TY - JOUR
T1 - Correction to
T2 - Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1 (Stem Cell Research and Therapy (2018) 9 (15) DOI: 10.1186/s13287-017-0759-z)
AU - Memon, Bushra
AU - Karam, Manale
AU - Al-Khawaga, Sara
AU - Abdelalim, Essam M.
N1 - Publisher Copyright:
© The Author(s). 2018.
PY - 2018/10/7
Y1 - 2018/10/7
N2 - The original article [1] contains a number of small errors which the authors would like to clarify: In Fig. 1a of the original article, FGF10 concentration should be 50 ng/ml as correctly stated in the Methods section instead of 100 ?g/ml. 2) Also in Fig. 1a of the original article, Activin A and EGF concentrations should both be 100 ng/ml as correctly stated in the Methods section instead of 100 ?g/ml. 3) In the Methods section under the sub-heading Differentiation of human pluripotent stem cells into pancreatic progenitor", the term, 50 ng/ml hFGF10 should be omitted from the following sentence: At the end of stage 3, media were changed to DMEM supplemented with 1% vol/vol B27, 0.25 mM vitamin C, 50 ng/ml hFGF10, 50 ng/ml hNOGGIN, 100 ng/ml EGF, and 10 mM nicotinamide (Sigma, USA) for 4 days of stage 4 treatment for each protocol (Fig. 1a)." FGF10 was only added during stages 2 & 3 of differentiation as correctly depicted in Fig. 1a. The corrected version of Fig. 1a can be viewed ahead. (Figure Presented).
AB - The original article [1] contains a number of small errors which the authors would like to clarify: In Fig. 1a of the original article, FGF10 concentration should be 50 ng/ml as correctly stated in the Methods section instead of 100 ?g/ml. 2) Also in Fig. 1a of the original article, Activin A and EGF concentrations should both be 100 ng/ml as correctly stated in the Methods section instead of 100 ?g/ml. 3) In the Methods section under the sub-heading Differentiation of human pluripotent stem cells into pancreatic progenitor", the term, 50 ng/ml hFGF10 should be omitted from the following sentence: At the end of stage 3, media were changed to DMEM supplemented with 1% vol/vol B27, 0.25 mM vitamin C, 50 ng/ml hFGF10, 50 ng/ml hNOGGIN, 100 ng/ml EGF, and 10 mM nicotinamide (Sigma, USA) for 4 days of stage 4 treatment for each protocol (Fig. 1a)." FGF10 was only added during stages 2 & 3 of differentiation as correctly depicted in Fig. 1a. The corrected version of Fig. 1a can be viewed ahead. (Figure Presented).
UR - http://www.scopus.com/inward/record.url?scp=85054433817&partnerID=8YFLogxK
U2 - 10.1186/s13287-018-1002-2
DO - 10.1186/s13287-018-1002-2
M3 - Comment/debate
C2 - 30292238
AN - SCOPUS:85054433817
SN - 1757-6512
VL - 9
JO - Stem Cell Research and Therapy
JF - Stem Cell Research and Therapy
IS - 1
M1 - 262
ER -